Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial.

[1]  S. Pilotti,et al.  Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma , 2015, Molecular oncology.

[2]  A. Paulussen,et al.  Acquired resistance to the Hedgehog pathway inhibitor vismodegib due to smoothened mutations in treatment of locally advanced basal cell carcinoma. , 2014, Journal of the American Academy of Dermatology.

[3]  A. Wysong,et al.  An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma. , 2014, Journal of the American Academy of Dermatology.

[4]  R. Dummer,et al.  Emerging drugs and combination strategies for basal cell carcinoma , 2014, Expert opinion on emerging drugs.

[5]  K. Peris,et al.  Update of the European guidelines for basal cell carcinoma management , 2014, European Journal of Dermatology.

[6]  A. Hauschild,et al.  Metastatic basal cell carcinoma: prognosis dependent on anatomic site and spread of disease. , 2014, European journal of cancer.

[7]  R. Dummer,et al.  A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors , 2014, Clinical Cancer Research.

[8]  M. Chren,et al.  Assessing health-related quality of life for advanced basal cell carcinoma and basal cell carcinoma nevus syndrome: development of the first disease-specific patient-reported outcome questionnaires. , 2014, JAMA dermatology.

[9]  J. Blay,et al.  GDC-0449 in patients with advanced chondrosarcomas: a French Sarcoma Group/US and French National Cancer Institute Single-Arm Phase II Collaborative Study. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  Aleksandar Sekulic,et al.  Advanced basal cell carcinoma of the skin: targeting the hedgehog pathway , 2013, Current Opinion in Oncology.

[11]  Aleksandar Sekulic,et al.  Efficacy and safety of vismodegib in advanced basal-cell carcinoma. , 2012, The New England journal of medicine.

[12]  J. Lear.  Oral hedgehog-pathway inhibitors for basal-cell carcinoma. , 2012, The New England journal of medicine.

[13]  C. Rudin,et al.  Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors , 2011, Clinical Cancer Research.

[14]  Jing Yuan,et al.  Interfering with Resistance to Smoothened Antagonists by Inhibition of the PI3K Pathway in Medulloblastoma , 2010, Science Translational Medicine.

[15]  M. Warmuth,et al.  Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist. , 2010, ACS medicinal chemistry letters.

[16]  Yun Yen,et al.  NCCN clinical practice guidelines in oncology: hepatobiliary cancers. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[17]  E. Epstein.  Basal cell carcinomas: attack of the hedgehog , 2008, Nature Reviews Cancer.

[18]  M. Wolter,et al.  Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas , 2005, The British journal of dermatology.

[19]  P. Fayers,et al.  Quality of life in head and neck cancer patients: validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-H&N35. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Michael Dean,et al.  Is human patched the gatekeeper of common skin cancers? , 1996, Nature Genetics.

[21]  D. Osoba,et al.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.

[22]  J. Hainsworth,et al.  Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib. , 2014, Journal of the American Academy of Dermatology.

[23]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.